Massachusetts Life Sciences Center’s Post

In our winter #lifesciences outlook, we examine: ⇛ Easing funding concerns for #biotechs ⇛ Global clinical trial challenges ⇛ Resilient revenue trends for #medtech

This must-read from Nature Review Drug Discovery breaks down the industrywide R&D spending in 2021, a landmark year in life sciences, with an estimated over $276B—six times the NIH budget and far surpassing the usual $100B figure from PhRMA surveys. Public commercial-stage firms led with 74% of total R&D spending, while private and development-stage companies also played significant roles. R&D intensity was 27% globally and 34% in the US—staggering numbers compared to other industries. This insightful paper highlights the immense investment and innovation driving the industry. #DrugDiscovery #RnDSpending #Pharma https://lnkd.in/gk6xWmFV

⚡ BioVid: Rapid Insights for Time-Sensitive Projects ⚡ As the year draws to a close, our clients can ensure their critical research needs are met with BioVid's rapid turnaround solutions. We specialize in delivering high-quality insights on tight deadlines, helping you meet end-of-year requirements without compromising on depth or accuracy. Quick-Turnaround Options - Our experienced team offers accelerated research in key areas: * Creative concept testing * Demand estimates * Meta-synthesis * Q4 burning questions With turnaround times of just 3-4 weeks, we provide actionable results to inform time-sensitive year-end decision-making. Our streamlined process ensures you receive the insights you need while meeting internal deadlines. Why Choose BioVid? Expertise: 5000+ projects in pharmaceutical and life sciences market research Agility: Flexible, adaptable processes customized to your timeline Quality: Cognitive Science-based methods for reliable insights Don't let time constraints hinder your research goals. Contact info@biovid.com today to discuss how our rapid turnaround options can drive your success in Q4. #MarketResearch #RapidInsights #Q4Strategy #DataDrivenDecisions #HealthcareResearch

Ranchers get to flex their science muscles next week at the #BioIT. Some as collaboration with our amazing customers. Come see them! We don't just clean data. We enable it! #dataintegrity #dataenablement P45: Utilizing NIIMBL and ISA-88 Framework to Create a Proof of Concept Pharmaceutical Manufacturing Ontology, Daniel (Danny) Cooper, Rancho BioSciences, Matthew Metzger, Merck P46: Streamlined Flow Cytometry Data QC Through Interactive Visualization, Presented by Michael A. Meier., Rancho BioSciences P47: Integrative Approach to Data Harmonization: Empowering Biomedical Research with Rancho Biosciences' Terminology Management Solution (TMS), Presented by Hillary Mosso, PhD., Rancho BioSciences P48: Accelerating Biomedical Discovery with Public Data: Single-Cell Data Science Consortium Harnesses Collective Expertise to Deliver Even More High Value Harmonized Datasets in Year 3, Presented by Dan Rozelle, Rancho BioSciences P49: Spatial Innovation Initiative Delivering Harmonized Analysis-Ready Datasets, Presented by Dan Rozelle, Rancho BioSciences P21: Unleashing Data's Full Potential Through Integrated Data Marts, Presented by Lasya S., Genentech

Yesterday Sixfold Bioscience also presented to the Society for Medicines Research on ‘The Innovation Landscape’ where UK discovery productivity and growth funding were on the agenda. Thanks to the SMR and Pharmidex, High Force Research Ltd and WuXi AppTec, session chairs from LifeArc, TherapeutAix who made the discussions worthwhile. It seems we all find innovation growth is a tough but irresistable journey - yes we do need more and varied funding models (a shout to Pioneer Group, MSD Pharma GmbH, BroadOak Capital Partners and Medicines Discovery Catapult here) and we all look forward to the economic ‘green shoots’.  As data tools accelerate the pace of innovation, let’s also recognise that we’ll face tough competition to attract and retain the UK and international scientific talent to make growth possible.

Interesting update from Disruptive Pharma AB on #MMC #Upsalite for drug delivery. The video is definitely worth a watch. Looking forward to the future developments. #PharmaInnovation #Healthcare #drugdelivery #drugformulation #biovailability

The Better Biotech Growth webinar series continues! Join my colleague Mark Kastner this Wednesday as he shares key steps to align pricing and reimbursement with scientific value. Learn how to navigate the global P&MA landscape to ensure your product reaches the patients who need it most. Don’t miss out: skp.link/9rxv #BetterBiotechGrowth #Biotech #CommercialExcellence #SimonKucher #BiotechGrowth

Should biotech companies consider pricing implications for Early Access Programs? In this snippet from our recent webinar with Fierce Biotech, Andrew Cummins (VP of Business Development) gives his expert thoughts and advice. Download valuable insights from our latest webinar! Visit: https://lnkd.in/eP4C3bFU #ExpandedAccessPrograms #RareDiseases #OrphanDrugs #RealWorldEvidence #MarketAccess #biotechs Mathieu Loiseau Sara Radenovic

🎉 Exciting News! 🎧 Our first episode is now live! In this episode, we're diving into the world of the pharmaceutical and biotech industries, breaking down some common industry jargon to help you navigate these complex fields with ease. Whether you're a seasoned professional or new to the industry, this episode has something for everyone! 👉 Check it out here and enhance your industry knowledge today: https://lnkd.in/g-3zku_h

Join Ed Harnaga from Pfizer at the upcoming Fierce Biotech Summit on Sept 30 - Oct 1 in Boston as he shares his expertise in groundbreaking biotech innovations and advancements. Register now and save up to $500 with the Early Bird Rate: https://ow.ly/uTAE50SyYgy Learn, Network and Connect over two jam-packed days with 500+ industry leaders and gain valuable insights into the future landscape of biotech. Stay Updated on all our events by following Fierce Life Sciences Events #FierceBiotechSummit #WeAreFierce #FierceBiotech #FierceBiotechSummit #BiotechInnovation #LifeSciences #PharmaIndustry #BiotechLeaders #Biotech2024 #BiotechTrends